Popular Articles

Royal Society Summer Science Exhibition: From Human Bite To Robot Jaws
The UK spends around ÷£2.5 billion each year on dental materials to replace or strengthen teeth*. The Chewing Robot is a new biologically inspired way to test dental materials and it will be shown to the public for the first time at this year"s Royal Society Summer Science Exhibition [30 June to 4 July].
generic viagra online
Pennsylvania Insurance Department Examinations To Focus On Health Insurance Competition
The Pennsylvania Insurance Department will conduct examinations of the state"s four Blue Cross and Blue Shield insurance companies, Blue Cross of Northeastern Pennsylvania, Capital BlueCross, Highmark, Inc. and Independence Blue Cross, to determine if any of them were engaged in anti-competitive or unfair trade practices in violation of the law, Insurance Commissioner Joel Ario announced today.
News of the day
US Oncology Research Network Participates In Phase III Follow-up Study To BiPar's Investigational Cancer Drug BSI-201
US Oncology, Inc. today announced that US Oncology Research will participate in the BiPar Sciences" Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer.
Health Insurance

Pluronic L-81: A Potential Anti-Diabetic Drug?

Pluronic surfactants are synthetic copolymers based on ethylene oxide and propylene oxide. It has been reported that a nonionic L-81, effectively inhibits absorption of dietary lipids from the intestine and secretion of VLDL and LDL from the liver. Although L-81 is a potent anti-obesity drug, its potential in alleviating obesity-induced insulin resistance and type 2 diabetes has not been fully explored. A research article published in the World Journal of Gastroenterology addresses this question. The research group led by Prof. Lin from the Department of Chemistry of the University of Hong Kong constructed db/db mice to investigate the potential anti-diabetic activity of L-81. In addition to exploration of the underlying molecular mechanism, they examined the effects of L-81 on apolipoprotein B (apoB) secretion and the mRNA level of the MTP gene. In their study, Genetically diabetic (db /db ) mice were fed on chow supplemented with or without L-81 for 4 wk. The body weight, plasma glucose level, plasma lipid profile, and adipocyte volume of the db /db mice were assessed after treatment. Toxicity of L-81 was also evaluated. To understand the molecular mechanism, HepG2 cells were treated with L-81 and the effects on apoB secretion and mRNA level of the MTP gene were assessed. The results revealed that L-81 significantly corrected the body weight, hyperphagia and polydipsia of db/db mice, and remarkably decreased the fasting plasma glucose level, improved glucose tolerance, and attenuated the elevated levels of plasma cholesterol and triglyceride. With the effective dosage, little toxicity was observed. Treatment on HepG2 cells with L-81 not only inhibited apoB secretion, but also significantly decreased the mRNA level of MTP gene. Similar to the action of insulin, L-81 exerted its effect on the MTP promoter. Their study L-81 is a promising candidate in the development of a selective insulin-mimetic molecule and an anti-diabetic agent. Reference: Au WS, Lu LW, Tam S, Ko OKH, Chow BKC, He ML, Ng SS, Yeung CM, Liu CC, Kung HF, Lin MC. Pluronic L-81 ameliorates diabetic symptoms in db/db mice through transcriptional regulation of microsomal triglyceride transfer protein. World J Gastroenterol 2009; 15(24): 2987-2994 Lai-Fu Li World Journal of Gastroenterology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):